Training Approach Sample Clauses

Training Approach. The framework is designed to guide learners to achieve an overall set of goals and then associates objectives and activities to achieve those overall goals, and evaluates the activities and results to be sure the goals were achieved.
AutoNDA by SimpleDocs
Training Approach. (a) The delivery of training to TTC, will be based on training a maximum of 5% of TTC employees. All training of TTC and operations support staff required for the PRESTO System will be mutually agreed and as completed in accordance to the Project Plan.
Training Approach. Client and PeopleSupport will jointly participate in the training needs analysis process with members from both teams to identify learning objectives and determine the scope of the training effort. Peoplesupport will certify all agents have passed a client approved curriculum. Client will make available all existing training and research documentation, training materials, and the knowledge base to PeopleSupport. All such materials and documentation will be deemed Client’s confidential information for purposes of Section 7 of the Agreement. Client will provide training materials and related documentation sufficient for PeopleSupport to conduct a successful training program. If necessary, and to assist in meeting Service Levels, PeopleSupport may update the Client training material or prepare a new course program with Client approval via the change order process. PeopleSupport will develop a training program for Client with the following capabilities: • Utilize the Client trainers and facility for the Train-the-Trainer session. • Provide instructors with extensive background in customer service, technical support, and sales, as well as stand up classroom training experience. • Provide customer service, sales and communications training, Client product/program training and pre-certification of agents prior to performing support for Client. • Establish a training and QA structure that supports Client’s program requirements. • Create a separate training environment that resembles the live Client environment, including individual workstations equipped with Client’s applications. All new eReps receive a PeopleSupport New Hire Orientation and the Client-specific training. After completion of the prescribed training, eReps will undergo a Nesting Period where Team Supervisors and trainers can observe and monitor such eReps closely before releasing them onto the production floor. The Nesting Period is estimated to be *** days in duration during which they will be handling a reasonable number of calls. The Client specific training and Nesting Period shall be billed at a *** rate as defined in Appendix A of this SOW.
Training Approach. A. WaMu and PeopleSupport will use a *** model to ensure that PeopleSupport trainers are capable of training Project Staff consistent with WaMu’s training standards. The *** model can generally be defined as a WaMu trainer certifying PeopleSupport trainers and WaMu and PeopleSupport trainers co-facilitating training retail and mortgage banking sessions with PeopleSupport Project Staff. Upon completion of Phase 5 of the Training Plan, the *** model will be deemed complete and the PeopleSupport trainers need to be certified by WaMu trainers.
Training Approach. A. WaMu and Supplier (which for convenience may be referred to as “PeopleSupport” in this Exhibit 16 and associated training plans) will use a *** model to ensure that PeopleSupport trainers are capable of training Project Staff consistent with WaMu’s training standards. The *** model can generally be defined as a WaMu trainer certifying PeopleSupport trainers and WaMu and PeopleSupport trainers co-facilitating training retail and mortgage banking sessions with PeopleSupport Project Staff. Upon completion of Phase 5 of the Training Plan, the *** model will be deemed complete and the PeopleSupport trainers need to be certified by WaMu trainers.
Training Approach. Infor will prepare Licensee Trainers to deliver the instructor-led and virtual training. As part of the Train-the-Trainer program, Infor will conduct workshops to introduce Licensee trainers to the blend of training components, classroom materials, instructional activities, and online resources that have been developed so the trainers become familiar with the structure of the courses and how each course element is used during the training event. Trainers will also can “teach back” key sections of the training and receive feedback on their performance, both to reinforce their understanding of the system and to practice their teaching skills in a safe setting. Activities associated with this approach are: • End-user Training Delivery The Training Delivery Plan, which will be developed with Licensee during the training development portion of each project phase, will provide the details regarding the approach and resources required for end-user training delivery. While a significant amount of the training can be deployed as self-paced learning, the delivery plan will address other ways to train and support Licensee employees through VILT “webinars” and coaching. With the large and dispersed Licensee employee population that will be impacted by the implementation, Infor recommends a “cascading” approach to delivering training and providing user support. Infor will develop Instructor guidelines and checklists for delivering the Manager and Employee training content, which Licensee Trainers from the Train-the-Trainer program can then use to train Licensee managers, who in turn can train and support their employees as needed using the same materials. • Knowledge Transfer Approach Infor will develop a knowledge transfer plan to facilitate the transfer of knowledge from the Infor training team to the internal Licensee team, to enable Licensee to transition to full support of the training program over a period. Through this process, Licensee team receives the following knowledge transfer components, which will enable Licensee to maintain the training solution over time: • Supporting materials, such as documentation standards and prototypes • Curriculum designSystem requirements and design specifications for the training tools • General training on the methodologies used to develop documentation and training • Training on and experience with the tools used to develop documentation and training • Staffing – End User Training The Infor training team will be engaged d...
Training Approach. Service Provider shall use a variety of approaches to develop consultants within Service Provider’s organization, with most training and development occurring informally within its organization. This informal training may include formal and informal mentoring, peer shadowing, special or “stretch” assignments, and local professional organization memberships and meetings. Service Provider shall regularly send consultants with COTS software expertise or development needs to user conferences or industry user group meetings. Service Provider shall also provide formal training, which may include formal classes through software vendors, college or university programs, or other registered training providers (e.g. Project Management Institute Project Management Professionals). When new staff are joining an existing project that Service Provider manages, Service Provider shall use the following approach:
AutoNDA by SimpleDocs
Training Approach 

Related to Training Approach

  • Regulatory Approval 25.1 The Parties understand and agree that this Agreement and any amendment or modification hereto will be filed with the Commission for approval in accordance with Section 252 of the Act and may thereafter be filed with the FCC. The Parties believe in good faith and agree that the services to be provided under this Agreement are in the public interest. Each Party covenants and agrees to fully support approval of this Agreement by the Commission or the FCC under Section 252 of the Act without modification.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Launch Customer shall use commercially reasonable efforts to begin distribution of the Google Desktop Applications promptly following the launch of the Desktop Portal.

  • Regulatory Milestones Celgene shall make the following approval milestone payments to Jounce that are set forth below upon the first achievement by or on behalf of Celgene, its Affiliates or Sublicensees of the Regulatory Milestone Events set forth below with respect to the first Co-Co Product that achieves such event. For clarity, each milestone set forth below shall be due and payable one time only (regardless of the number of Co-Co Products to achieve any such Regulatory Milestone Event). CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Regulatory Milestone Event (For the first Co-Co Product that achieves such event) Milestone Payments (in $ millions) [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] For each of Paragraphs (1) - (3) of this Exhibit C-2, the Parties understand and agree that in no event will more than one (1) milestone payment be paid with respect to any specific event triggering a payment under this Jounce Lead Co-Co Agreement.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Licensed Territory Worldwide NIH Patent License Agreement—Exclusive APPENDIX C – ROYALTIES Royalties:

  • Regulatory Approvals; Efforts (a) Prior to the Closing, Parent, Merger Sub and the Company shall use their respective reasonable best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things necessary, proper or advisable under any applicable Laws to consummate and make effective the Merger including (i) the preparation and filing of all forms, registrations and notices required to be filed to consummate the Merger, (ii) the satisfaction of the conditions to consummating the Merger, (iii) taking all reasonable actions necessary to obtain (and cooperating with each other in obtaining) any consent, authorization, Order or approval of, or any exemption by, any third party, including any Governmental Entity (which actions shall include furnishing all information and documentary material required under the HSR Act) required to be obtained or made by Parent, Merger Sub, the Company or any of their respective Subsidiaries in connection with the Merger or the taking of any action contemplated by this Agreement, and (iv) the execution and delivery of any additional instruments necessary to consummate the Merger and to fully carry out the purposes of this Agreement. Additionally, each of Parent, Merger Sub and the Company shall use reasonable best efforts to fulfill all conditions precedent to the Merger and shall not take any action after the date of this Agreement that would reasonably be expected to materially delay the obtaining of, or result in not obtaining, any permission, approval or consent from any such Governmental Entity necessary to be obtained prior to Closing. To the extent that transfers of any permits issued by any Governmental Entity are required as a result of the execution of this Agreement or the consummation of the Merger, the parties hereto shall use reasonable best efforts to effect such transfers.

  • Development and Regulatory Milestones With respect to each of the following milestones, Ikaria shall pay BioLineRx the corresponding payment set forth below within [**] days after the achievement by Ikaria, its Affiliates or Licensees of such milestone: MILESTONE PAYMENT

  • Regulatory Applications (a) Sky and SBI and their respective Subsidiaries shall cooperate and use their respective reasonable best efforts to prepare, within 45 days of the execution of this Agreement, all documentation and requests for regulatory approval, to timely effect all filings and to obtain all permits, consents, approvals and authorizations of all third parties and Governmental Authorities and Regulatory Authorities necessary to consummate the transactions contemplated by this Agreement. Each of Sky and SBI shall have the right to review in advance, and to the extent practicable each will consult with the other, in each case subject to applicable laws relating to the exchange of information, with respect to, and shall be provided in advance so as to reasonably exercise its right to review in advance, all material written information submitted to any third party or any Governmental Authority or Regulatory Authority in connection with the transactions contemplated by this Agreement. In exercising the foregoing right, each of the parties hereto agrees to act reasonably and as promptly as practicable. Each party hereto agrees that it will consult with the other party hereto with respect to the obtaining of all material permits, consents, approvals and authorizations of all third parties and Governmental Authorities or Regulatory Authorities necessary or advisable to consummate the transactions contemplated by this Agreement and each party will keep the other party apprised of the status of material matters relating to completion of the transactions contemplated hereby.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!